Use of cancer stem cells to investigate the pathogenesis of colitis-associated cancer

Inflammatory Bowel Diseases

Volumn 22, Issue 4, 2016, Pages 976-983

  Davies, Julie M ^a   Santaolalla, Rebeca ^a   Abreu, Maria T ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

APC; colitis associated cancer; colonoid; enteroid; inflammation; Lgr5; stem cells; catenin

Indexed keywords

ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER STEM CELL; CARCINOGENESIS; COLITIS ASSOCIATED CANCER; COLON CANCER; DRUG RESISTANCE; GENETIC TRANSFORMATION; HOMEOSTASIS; HUMAN; IMMUNOFLUORESCENCE; IN VITRO STUDY; INTESTINAL STEM CELL; MEDICAL HISTORY; NONHUMAN; OUTCOME ASSESSMENT; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; TUMOR MICROENVIRONMENT; ULCERATIVE COLITIS; ANIMAL; COLITIS; COLONIC NEOPLASMS; COMPLICATION; INTESTINE; PATHOLOGY;

ANIMALS; COLITIS; COLONIC NEOPLASMS; HUMANS; INTESTINES; NEOPLASTIC STEM CELLS;

EID: 84962269057     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000756     Document Type: Article

References (77)

1. Haggar FA, Boushey RP. Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg. 2009;22: 191-197.
2. Huxley RR, Ansary-Moghaddam A, Clifton P, et al. The impact of dietary and lifestyle risk factors on risk of colorectal cancer: a quantitative overview of the epidemiological evidence. Int J Cancer. 2009;125:171-180.
3. Flood DM, Weiss NS, Cook LS, et al. Colorectal cancer incidence in Asian migrants to the United States and their descendants. Cancer Causes Control. 2000;11:403-411.
4. Ladabaum U, Clarke CA, Press DJ, et al. Colorectal cancer incidence in Asian populations in California: effect of nativity and neighborhood-level factors. Am J Gastroenterol. 2014;109:579-588.
5. Jess T, Rungoe C, Peyrin-Biroulet L. Risk of colorectal cancer in patients with ulcerative colitis: a meta-Analysis of population-based cohort studies. Clin Gastroenterol Hepatol. 2012;10:639-645.
6. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-Analysis. Gut. 2001;48:526-535.
7. Rogler G. Chronic ulcerative colitis and colorectal cancer. Cancer Lett. 2014;345:235-241.
8. Andersen NN, Jess T. Has the risk of colorectal cancer in inflammatory bowel disease decreased?. World J Gastroenterol. 2013;19:7561-7568.
9. Winther KV, Jess T, Langholz E, et al. Long-Term risk of cancer in ulcerative colitis: a population-based cohort study from Copenhagen County. Clin Gastroenterol Hepatol. 2004;2:1088-1095.
10. Castano-Milla C, Chaparro M, Gisbert JP. Systematic review with metaanalysis: the declining risk of colorectal cancer in ulcerative colitis. Aliment Pharmacol Ther. 2014;39:645-659.
11. Velayos FS, Terdiman JP, Walsh JM. Effect of 5-Aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol. 2005;100:1345-1353.
12. Beaugerie L, Svrcek M, Seksik P, et al. Risk of colorectal high-grade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel disease. Gastroenterology. 2013;145:166-175.e168.
13. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61:759-767.
14. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell. 1996;87:159-170.
15. Fogt F, Vortmeyer AO, Goldman H, et al. Comparison of genetic alterations in colonic adenoma and ulcerative colitis-Associated dysplasia and carcinoma. Hum Pathol. 1998;29:131-136.
16. Tarmin L, Yin J, Harpaz N, et al. Adenomatous polyposis coli gene mutations in ulcerative colitis-Associated dysplasias and cancers versus sporadic colon neoplasms. Cancer Res. 1995;55:2035-2038.
17. Terzic J, Grivennikov S, Karin E, et al. Inflammation and colon cancer. Gastroenterology. 2010;138:2101-2114.e2105.
18. Ullman TA, Itzkowitz SH. Intestinal inflammation and cancer. Gastroenterology. 2011;140:1807-1816.
19. Herbst A, Jurinovic V, Krebs S, et al. Comprehensive analysis of betacatenin target genes in colorectal carcinoma cell lines with deregulated Wnt/beta-catenin signaling. BMC Genomics. 2014;15:74.
20. MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Developmental Cell. 2009;17:9-26.
21. Mosimann C, Hausmann G, Basler K. Beta-catenin hits chromatin: regulation of Wnt target gene activation. Nat Rev Mol Cell Biol. 2009; 10:276-286.
22. McKenzie SJ, Baker MS, Buffinton GD, et al. Evidence of oxidantinduced injury to epithelial cells during inflammatory bowel disease. J Clin Invest. 1996;98:136-141.
23. Marnett LJ. Oxyradicals and DNA damage. Carcinogenesis. 2000;21: 361-370.
24. Kiraly O, Gong G, Olipitz W, et al. Inflammation-induced cell proliferation potentiates DNA damage-induced mutations in vivo. PLoS Genetics. 2015;11:e1004901.
25. Du Q, Geller DA. Cross-regulation between wnt and NF-kappaB signaling pathways. For Immunopathol Dis Therap. 2010;1:155-181.
26. Kaler P, Augenlicht L, Klampfer L. Macrophage-Derived IL-1beta stimulates Wnt signaling and growth of colon cancer cells: a crosstalk interrupted by vitamin D3. Oncogene. 2009;28:3892-3902.
27. Oguma K, Oshima H, Aoki M, et al. Activated macrophages promote Wnt signalling through tumour necrosis factor-Alpha in gastric tumour cells. EMBO J. 2008;27:1671-1681.
28. Santaolalla R, Sussman DA, Ruiz JR, et al. TLR4 activates the betacatenin pathway to cause intestinal neoplasia. PLoS One. 2013;8: e63298.
29. Sansom OJ, Reed KR, Hayes AJ, et al. Loss of Apc in vivo immediately perturbs Wnt signaling, differentiation, and migration. Genes Dev. 2004; 18:1385-1390.
30. Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al. Identification and expansion of human colon-cancer-initiating cells. Nature. 2007;445:111-115.
31. O?Brien CA, Pollett A, Gallinger S, et al. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 2007;445:106-110.
32. Dalerba P, Dylla SJ, Park IK, et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci U S A. 2007;104:10158-10163.
33. Levin TG, Powell AE, Davies PS, et al. Characterization of the intestinal cancer stem cell marker CD166 in the human and mouse gastrointestinal tract. Gastroenterology. 2010;139:2072-2082.e2075.
34. Haraguchi N, Ishii H, Mimori K, et al. CD49f-positive cell population efficiently enriches colon cancer-initiating cells. Int J Oncol. 2013;43: 425-430.
35. Huang EH, Hynes MJ, Zhang T, et al. Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res. 2009; 69:3382-3389.
36. Wang C, Xie J, Guo J, et al. Evaluation of CD44 and CD133 as cancer stem cell markers for colorectal cancer. Oncol Rep. 2012;28:1301-1308.
37. Muraro MG, Mele V, Daster S, et al. CD133+, CD166+CD44+, and CD24+CD44+ phenotypes fail to reliably identify cell populations with cancer stem cell functional features in established human colorectal cancer cell lines. Stem Cells Transl Med. 2012;1:592-603.
38. Barker N, van Es JH, Kuipers J, et al. Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature. 2007;449:1003-1007.
39. Van der Flier LG, Sabates-Bellver J, Oving I, et al. The intestinal Wnt/TCF signature. Gastroenterology. 2007;132:628-632.
40. Yan KS, Chia LA, Li X, et al. The intestinal stem cell markers Bmi1 and Lgr5 identify two functionally distinct populations. Proc Natl Acad Sci U S A. 2012;109:466-471.
41. Powell AE, Wang Y, Li Y, et al. The pan-ErbB negative regulator Lrig1 is an intestinal stem cell marker that functions as a tumor suppressor. Cell. 2012;149:146-158.
42. Zhu Y, Huang YF, Kek C, et al. Apoptosis differently affects lineage tracing of Lgr5 and Bmi1 intestinal stem cell populations. Cell Stem Cell. 2013;12:298-303.
43. Barker N, Ridgway RA, van Es JH, et al. Crypt stem cells as the cells-oforigin of intestinal cancer. Nature. 2009;457:608-611.
44. Schwitalla S, Fingerle AA, Cammareri P, et al. Intestinal tumorigenesis initiated by dedifferentiation and acquisition of stem-cell-like properties. Cell. 2013;152:25-38.
45. Choi JW, Kim JK, Choi M, et al. In vivo imaging of Lgr5-positive cell populations using confocal laser endomicroscopy during early colon tumorigenesis. Endoscopy. 2014;46:1110-1116.
46. Hirsch D, Barker N, McNeil N, et al. LGR5 positivity defines stem-like cells in colorectal cancer. Carcinogenesis. 2014;35:849-858.
47. Sato T, Vries RG, Snippert HJ, et al. Single Lgr5 stem cells build cryptvillus structures in vitro without a mesenchymal niche. Nature. 2009;459: 262-265.
48. Fuller MK, Faulk DM, Sundaram N, et al. Intestinal crypts reproducibly expand in culture. J Surg Res. 2012;178:48-54.
49. Middendorp S, Schneeberger K, Wiegerinck CL, et al. Adult stem cells in the small intestine are intrinsically programmed with their locationspecific function. Stem Cells. 2014;32:1083-1091.
50. Davies JM, Santaolalla R, von Furstenberg RJ, et al. The viral mimetic polyinosinic: polycytidylic acid alters the growth characteristics of small intestinal and colonic crypt cultures. PLoS One. 2015;10:e0138531.
51. Sato T, Stange DE, Ferrante M, et al. Long-Term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett?s epithelium. Gastroenterology. 2011;141:1762-1772.
52. Gonzalez LM, Williamson I, Piedrahita JA, et al. Cell lineage identification and stem cell culture in a porcine model for the study of intestinal epithelial regeneration. PLoS One. 2013;8:e66465.
53. Dekkers JF, Wiegerinck CL, de Jonge HR, et al. A functional CFTR assay using primary cystic fibrosis intestinal organoids. Nat Med. 2013;19:939-945.
54. VanDussen KL, Marinshaw JM, Shaikh N, et al. Development of an enhanced human gastrointestinal epithelial culture system to facilitate patient-based assays. Gut. 2015;64:911-920.
55. Moon C, VanDussen KL, Miyoshi H, et al. Development of a primary mouse intestinal epithelial cell monolayer culture system to evaluate factors that modulate IgA transcytosis. Mucosal Immunol. 2014;7:818-828.
56. Grabinger T, Luks L, Kostadinova F, et al. Ex vivo culture of intestinal crypt organoids as a model system for assessing cell death induction in intestinal epithelial cells and enteropathy. Cell Death Dis. 2014;5:e1228.
57. Foulke-Abel J, In J, Kovbasnjuk O, et al. Human enteroids as an ex-vivo model of host-pathogen interactions in the gastrointestinal tract. Exp Biol Med (Maywood). 2014;239:1124-1134.
58. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126:663-676.
59. Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131:861-872.
60. Yu J, Vodyanik MA, Smuga-Otto K, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007;318:1917-1920.
61. Miyazaki S, Yamamoto H, Miyoshi N, et al. Emerging methods for preparing iPS cells. Jpn J Clin Oncol. 2012;42:773-779.
62. Okita K, Hong H, Takahashi K, et al. Generation of mouse-induced pluripotent stem cells with plasmid vectors. Nat Protoc. 2010;5:418-428.
63. Takahashi K, Okita K, Nakagawa M, et al. Induction of pluripotent stem cells from fibroblast cultures. Nat Protocols. 2007;2:3081-3089.
64. Marti M, Mulero L, Pardo C, et al. Characterization of pluripotent stem cells. Nat Protoc. 2013;8:223-253.
65. Kim JJ. Applications of iPSCs in Cancer research. Biomark Insights. 2015;10:125-131.
66. Miyoshi N, Ishii H, Nagai K, et al. Defined factors induce reprogramming of gastrointestinal cancer cells. Proc Natl Acad Sci U S A. 2010; 107:40-45.
67. Kim J, Hoffman JP, Alpaugh RK, et al. An iPSC line from human pancreatic ductal adenocarcinoma undergoes early to invasive stages of pancreatic cancer progression. Cell Rep. 2013;3:2088-2099.
68. Spence JR, Mayhew CN, Rankin SA, et al. Directed differentiation of human pluripotent stem cells into intestinal tissue in vitro. Nature. 2011; 470:105-109.
69. McCracken KW, Howell JC, Wells JM, et al. Generating human intestinal tissue from pluripotent stem cells in vitro. Nat Protoc. 2011;6: 1920-1928.
70. Ogaki S, Shiraki N, Kume K, et al. Wnt and Notch signals guide embryonic stem cell differentiation into the intestinal lineages. Stem Cells. 2013; 31:1086-1096.
71. Rodansky ES, Johnson LA, Huang S, et al. Intestinal organoids: a model of intestinal fibrosis for evaluating anti-fibrotic drugs. Exp Mol Pathol. 2015;98:346-351.
72. Miyoshi H, Stappenbeck TS. In vitro expansion and genetic modification of gastrointestinal stem cells in spheroid culture. Nat Protoc. 2013;8: 2471-2482.
73. Matano M, Date S, Shimokawa M, et al. Modeling colorectal cancer using CRISPR-Cas9-mediated engineering of human intestinal organoids. Nat Med. 2015;21:256-262.
74. Drost J, van Jaarsveld RH, Ponsioen B, et al. Sequential cancer mutations in cultured human intestinal stem cells. Nature. 2015;521:43-47.
75. Ayyaz A, Li H, Jasper H. Haemocytes control stem cell activity in the Drosophila intestine. Nat Cell Biol. 2015;17:736-748.
76. Skoczek DA, Walczysko P, Horn N, et al. Luminal microbes promote monocyte-stem cell interactions across a healthy colonic epithelium. J Immunol. 2014;193:439-451.
77. Choi J, Yoon SH, Kim JE, et al. Gene-specific oxidative DNA damage in Helicobacter pylori-infected human gastric mucosa. Int J Cancer. 2002; 99:485-490.